Luminal B-HER2+型乳腺癌的治疗进展

Review on the Treatment of Luminal B-HER2+ Subtype Breast Cancer

乳腺癌是一种激素依赖性并且高度异质性的恶性肿瘤。内分泌治疗是重要治疗手段之一,尤其对于Luminal A型和Luminal B型乳腺癌患者。其中Luminal B型乳腺癌又分为Luminal B-HER2-型和Luminal B-HER2+型,后者新辅助/辅助治疗上可以应用化疗、内分泌治疗以及抗HER2靶向治疗,但是部分人群对化疗不敏感,内分泌以及靶向HER2治疗耐药,已成为临床上的瓶颈。本文总结了近年国内外针对此类型乳腺癌的探索耐药机制的新进展以及治疗方案。

As breast cancer is a hormone-dependent malignant tumor and has high heterogeneity,ajuvant endocrine therapy is an important treatment strategy,especially for those with Luminal A and Luminal B. Luminal B can be further classified into two subtypes（HER2 negative and HER2positive） according to the expression status of HER2. Although the treatments to patients with the latter subtype including neo/adjuvant chemotherapy,endocrine therapy and anti-HER2 therapy.The hypo-activation to chemotherapy and primary resistance to endocrine therapy and anti-HER2 therapy have puzzled the physicians. This article is due to summarize the updated researches relevant to mechanism of the hypo-activation and resistance and treatment strategies in recent years.